Phase III confirmatory efficacy and safety study of proposed bevacizumab biosimilar (MYL-1402O) compared with avastin, in the first-line treatment of patients with stage IV non-squamous non-small cell lung cancer (nsNSCLC) Meeting Abstract

International Collaboration

cited authors

  • Socinski, M. A.; Waller, C.; Idris, T.; Bondarenko, I.; Luft, A.; Beckmann, K.; Vishweswaramurthy, A.; Loganathan, S.; Ranganna, G.; Barve, A.

authors

Publication Date

  • September 1, 2020

webpage

published in

category

start page

  • S883

end page

  • S884

volume

  • 31